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To assess the utility of vaccinia virus recombinants in the development of an immune response against HPV capsid 
antigens, 5-week-old C57B16 female mice were administered either purified HPV 1 capsids produced by a vaccinia virus 
recombinant or the recombinant vaccinia virus itself. Animals were boosted at Week 4 with either agent. Mice developed 
a serum IgG antibody response in all the administration protocols that was directed mainly against native L1 epitopes. Mice 
injected initially with the vaccinia virus recombinant and boosted with purified ~;apsids had a higher titer antibody response 
(P = 0.024) with more mice responding to a greater extent. All mice produced a serum IgM response that preceded the 
IgG response by approximately 2 weeks and lasted 1-3  weeks. The IgM response was directed against native L1 epitopes. 
Although no serum IgA was detected, IgA could be detected in vaginal secretions of mice that were immunized or boosted 
with the vaccinia virus vector. These results indicate that an extensive humoral immune response to HPV can be elicited 
using vaccinia virus recombinants. © 1995 Academic Press, Inc. 
INTRODUCTION 
Human papillomaviruses (HPV) are a heterogeneous 
group of double-stranded DNA viruses that are associ- 
ated with benign and malignant lesions of the anogenital 
tract as well as being responsible for common and foot 
warts (Koutsky eta/., 1988; zur Hausen, 1991). HPVtypes 
1 and 2 are found in common warts, types 6 and 11 are 
found in condylomata accuminata, and types 16, 18, and 
others are seen in anogenital malignancies (zur Hausen, 
1991). Studies on HPV have been hampered bythe inabil- 
ityto propagate the virus in culture. Recently, a number of 
investigators have demonstrated the production of HPV 
capsids by utilizing baculovirus or vaccinia virus expres- 
sion systems (Zhou eta/., 1991a; Kirnbauer eta/., 1992; 
Hagensee et a/., 1993; Rose et al., 1993). These in vitro- 
produced capsids appear to have an identical structure 
to authentic virions being composed of the major (L1) 
and minor (L2) capsid proteins (Hagensee eta/., 1993, 
1994). These capsids are currently being used to develop 
serological assays for HPV infections (Rose et a/., 1993; 
Kirnbauer eta/., 1994; Carter et aL, 1994; Carter et aL, 
manuscript in preparation). 
The study of the immune response to HPV has addi- 
tionally been complicated bythe lack of an animal model. 
Vaccination experiments utilizing the related bovine pap- 
illomavirus (BPV) or cottontail rabbit papillomavirus 
(CRPV) have shown great variation in the response ob- 
tained with results depending on the type of immunogen, 
the route of administration, and the adjuvant used. Pila- 
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cinski et al. (1986) showed that calves immunized intra- 
muscularly with a BPV 1 L1-/3-galactosidase fusion pro- 
tein made in Escherichia coil had fewer warts than con- 
trol animals. Jin etaL (1990), using a similar fusion protein 
given intradermally, showed stabilization or decreased 
fibroma size as compared to an increasing size of fibro- 
mas in control calves. They noted the best response 
depended on the type of adjuvant used rather than the 
conformational state of the fusion protein. Protection has 
been seen using an E. co/i-derived BPV 2 L1-/~-galactosi- 
dase fusion protein (Jarrett eta/., 1991) given intramuscu- 
larly and challenged with BPV 2. In addition, immuniza- 
tion with a L2 fusion protein caused regression of estab- 
lished tumors with concomitant lymphocytic infiltration 
of the lesion. Initial studies with CRPV (Christensen et 
a/., 1991) noted protection of rabbits when administering 
a CRPV L2 fusion protein with no protection seen using 
an L1 fusion protein. However, subsequent studies (Lin 
eta/., 1992) utilizing a larger fragment of the CRPV L1 
protein demonstrated protection that was only seen with 
a full-length, nondenatured product (Lin eta/., 1993). 
A better understanding of mucosal immunity is essen- 
tial for the development of vaccines for sexually transmit- 
ted diseases (STDs) such as Chlamydia trachomatis, her- 
pes simplex virus (HSV), and HPV. Initial studies in hu- 
mans with C. trachomatis noted an inverse correlation 
between cervical secretory IgA levels and the recovery 
of organisms from the genital tract (Brunham et al., 1983). 
Using a mouse model (Cui etaL, 1991), it has been shown 
that oral inoculation with C. trachomatis led to an anti ~ 
body response at many mucosal sites including the cer- 
vix with subsequent protection from pulmonary disease 
(Cui et aL, 1989). A similar inverse correlation between 
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cervical IgA and recovery of HSV from humans has also 
been seen (Merriman et al., 1984). Additional studies 
using either mouse or guinea pig models of HSV have 
shown the development of mucosat antibody after infec- 
tion with HSV (McBride et aL, 1988; McDermott eta/., 
1990). Vaccination with various HSV glycoproteins as ei- 
ther purified protein (Stanberry et a/., 1989) or vaccinia 
virus recombinant (Paoletti et aL, 1984; Wachsman et al., 
1987; Weir et aL, 1989) has led to protection from HSV 
infection. 
The mucosal response to HPV infection has been stud- 
ied using denatured synthetic peptides (Dillner et al., 
1989), bacterial fusion proteins (Snyder eta/., 1991), or 
aPVvirions (Dillner eta/., 1993) as antigen. Cervical IgA 
antibody responses were detected and were more preva- 
lent in patients with cervical intraepithelial neoplasia 
(01N). The significance of these findings is not clear due 
to recent studies underscoring the importance of confor- 
mational epitopes (Rose et al., 1993; Kirnbauer et aL, 
1994; Carter etaL, 1994) and data demonstrating that the 
majority of the human serologic response is HPV type 
specific (Galloway and Jenison, 1990). Capsids (Zhou et 
a/., 1991b; Kirnbauer et al., 1992) and HPV virions pro- 
duced in a nude mouse model (Christensen et a/., 1990) 
have been utilized to generate antibodies to papillomavi- 
rus capsids. These studies did not characterize the tim- 
ing of the serologic response to the papillomavirus anti- 
gen nor did they measure mucosal immunity. In this re- 
port, we have investigated the immune response in mice 
to HPV 1 late proteins presented either as a recombinant 
vaccinia virus or as purified capsid. We find that either 
preparation produced a significant antibody response 
butthe vaccinia virus recombinant given initially followed 
by purified capsids had the highest IgG titer. In addition, 
a mucosal IgA immune response was only seen in mice 
that were exposed to the vaccinia virus recombinant. 
MATERIALS AND METHODS 
Mice 
Fifty-one female C57B16 mice, 4 weeks old, free of 
animal viruses were observed for 4 weeks prior to vacci- 
nation. All animals were bled prior to administration of 
antigen. 
Cells and virus 
0ells (BSC-1) were grown in Dulbeco's modified Ea- 
gles's medium with 5% fetal bovine serum. Vaccinia virus 
recombinants (vac-MJ1L1L2) expressing the HPV 1 L1 
and L2 proteins were produced as described (Hagensee 
et al., 1993). These recombinants as well as wild-type 
vaccinia virus (vNY) were diluted in phosphate-buffered 
saline (PBS) to the appropriate concentration and intro- 
duced into the mice by tail scarification (Hu eta/., 1991). 
HPV 1 capsids containing only the L1 protein or both 
the L1 and L2 proteins were purified from vaccinia virus 
recombinant-infected cells (Hagensee et aL, 1993). Con- 
taminating vaccinia viruses were killed by uv irradiation 
and verified by post-irradiation titering on BSC-I cells. 
The resulting antigen contained less than 101 PFU/ml of 
vaccinia virus. 
Experimental design 
The experimental protocol is similar to that used by 
Hu eta/. (1991a) for antibody responses to human immu- 
nodeficiency virus type 1 (HIV 1) surface proteins. Mice 
were divided randomly into five groups (Table 1). Groups 
1 (8 mice) and 2 (9 mice) received 108 PFU/ml of vac- 
M J1 L1/1 L2 via tail scarification. Groups 3 and 4 (10 mice 
each) received 50 #g of purified HPV 1 capsids mixed 
1=1 with complete Freund's adjuvant via subcutaneous 
injection. Groups 1 and 3 were subsequently boosted at 
Week 4 with 108 PFU/ml of vac-MJ1 L1/1 L2 by tail scarifi- 
cation, where'as groups 2 and 4 received a boost of 50 
#g of purified HPV 1 capsids mixed 1,1 with incomplete 
Freund's adjuvant given subcutaneously. Group 5 (11 ani- 
mals) was administered 108 PFU/ml of wild-type vaccinia 
virus (vNY) by scarification initially and as a boost at 
Week 4. Sera were collected from the retroorbital venous 
plexus at weekly intervals into Microtainer (Becton-Dick- 
inson) serum separator tubes, spun, transferred to 0.5- 
ml cryotubes (Fisher), and stored at 4 ° until analyzed. 
Cervical secretions were collected by washing the vagi- 
nal opening with 10 #1 of sterile PBS (Cui eta/., 1991). 
ELISA 
Cesium chloride gradient-purified HPV 1 L1 or L1L2 
capsids were diluted in PBS to a concentration that was 
determined to be saturating (higher concentrations of 
capsids did not result in higher ELISA values) and 50 #1 
was applied to an Immulon 2 microtiter plate (Dynatech 
Laboratories, Inc., Chantilly, VA). The plates were incu- 
bated overnight at room temperature and washed three 
times with PBS. The plates were treated with blocking 
agent (PBS with 5% goat serum (Sigma), 0,5% nonfat dry 
milk (Carnation), 0.05% Tween 20 (polyosyethylene-sorbi- 
tan monolauratem, Sigma)) for 1 hr at room temperature 
to inhibit nonspecific binding. The blocking agent was 
removed and mouse serum diluted 1=100 in the blocking 
buffer was added 50 #1 per well. The plates were incu- 
bated for 2 hr at room temperature followed by washing 
as before. Goat anti-mouse IgG-aikaline phosphatase 
(Boehringer-Mannheim) was added in blocking agent at 
a dilution of 1:1000 and 100 #1 was added per well. The 
plates were incubated for 1 hr at 37 ° and washed as 
before. The color development and readings were con- 
ducted as described previously (Carter et aL, 1994). The 
optical density for each serum sample was calculated 
as the average of the reading in the wells containing 
capsids minus the average of the readings in the wells 
without capsids. A positive serum was defined as an 
ELISA value that was higher than two standard devia- 
176 HAGENSEE ET AL. 
TABLE 1 
IMMUNIZATION PROTOCOL 
Group No. of mice Week 0 Week 4 
1 8 vac-MJ 1 L1 L2 vac-MJ 1 L1 L2 
2 9 vac-MJ 1 L1 L2 L1 L2 capsids 
3 10 L1 L2 capsids vac-MJ 1 L1 L2 
4 10 L1 L2 capsids L1 L2 capsids 
5 11 vac-NY (wt) vac-NY (wt) 
tions above control animals. Endpoint titers could not be 
performed on all mice, at all time points due to the lack 
of sufficient sera. IgM and IgA responses were similarly 
assayed utilizing HPV 1 L1L2 capsids as antigen and 
either goat anti-mouse IgM-alkaline phosphatase 
(Boehringer-Mannheim) or goat-anti-mouse IgA-alkaline 
phosphatase (Sigma) as second antibody at a dilution 
of 1=1000. ELISAs of denatured proteins used purified 
capsids diluted in carbonate buffer (0.1 M, pH 9.5). Statis- 
tical methods utilized either one-tail or two-tailed Stu- 
dent's t test assuming unequal variances. A P value of 
less than 0.05 was deemed significant. 
Immunoblots 
The HPV 1 L1 and L2 trpE fusion protein expression 
constructs used here were previously described (Yae- 
gashi et aL, 1991) and immunoblotting was performed 
as described previously (Jenison et al., 1988) with the 
following modifications= Mouse sera were diluted 1=200 
in blotto and incubated overnight a 4 ° with nitrocellulose 
blots prepared previously. The secondary antibody was 
horseradish peroxidase-linked goat anti-mouse (Boeh- 
ringer-Mannheim Corp., Indianapolis, IN) at a dilution of 
1=20,000 in PBS with 5% nonfat dry milk (Carnation) and 
0.01% Tween 20 that was incubated with the blot for 2 
hr at room temperature. The development of the blots 
was performed using the Renaissance chemilumines- 
cence kit (Du Pont, NEN, Boston, MA) following the man- 
ufacturer's protocol. Each blot contained molecular 
weight markers, the insoluble fraction from cells express- 
ing the trpE protein, the trpE-1L1 fusion protein, and the 
trpE-1L2 fusion protein. The amount of protein in each 
lane was normalized by comparison of amido black- 
stained blots. A positive serum showed reaction to trpE- 
1L1 or -1L2 fusion protein at the appropriate molecular 
weight and no reaction to the trpE protein alone. 
RESULTS 
Serum IgG response 
Mice were exposed to HPV 1 proteins according to 
the protocol outlined under Materials and Methods and 
Table 1. All mice that received HPV 1 late proteins as 
either purified capsid or recombinant vaccinia virus de- 
veloped an IgG antibody response (Fig. 1). Administration 
of the vaccinia virus recombinant first (groups 1 (vac/ 
vac) and 2 (vac/cap)) led to a slightly higher average 
reactivity at Week 4 than the use of purified protein. This 
was statistically significant when comparing group 1 
(vac/vac) with group 3 (cap/vac, P = 0.011) or group 4 
(cap/cap, P = 0.0016) as well as when comparing group 
2 with group 4 (P = 0.019). The IgG response increased 
in groups 1-4 after the boost at Week 4 with the greatest 
rise being in groups 3 (cap/vac) and 4 (cap/cap). The 
control group 5 (vNY/vNY) showed only a minimal re- 
sponse that was felt to be directed against contaminating 
vaccinia proteins. 
Individual mouse responses are shown in Fig. 2. All 
four groups showed mouse-to-mouse variability in the 
degree and timing of an antibody response. Group 2 
(vac/cap) showed the least variability (smallest standard 
deviations) in the development of an antibody response, 
with more mice responding to a greater extent. Group 4 
(cap/cap) showed the most variability, with three mice 
(open square, closed triangle, open circle) showing only 
a marginal response. The titer of the antibody response 
was measured at Week 7 (Fig. 3) against HPV 1 L1 cap- 
sids. The titers were similar in all experimental groups 
except for group 2 (vac/cap) that demonstrated a slightly 
higher titer that was only significantly different from group 
3 (P = 0.024). 
Characterization of the reacting epitope(s) 
The antigenic site(s) that produced the IgG response 
was initially investigated by comparing the ELISA reactiv- 
ity to native HPV 1 L1 capsids (PBS buffer) with reactivity 
to denatured L1 capsids (carbonate buffer). A control 
rabbit polyclonal serum made against purified HPVl 
L1L2 capsids reacted equally well with native or dena- 
tured capsid preparations. In all mice tested, the reactiv- 
ity decreased when assaying with denatured capsids 
(data not shown) implying that a conformational epi- 
tope(s) was being recognized. By scoring positive ELISA 
reactivity as an optical density greater than two times 
the standard deviation of control animals, six of eight 
group 1 (vac/vac) animals and four of nine group 2 (vae/ 
cap) animals responded to a denatured epitope(s) (Table 
2). By this criterion, no sera from animals in either group 
3 (cap/vac) or group 4 (cap/cap) responded to denatured 
epitope(s). 
Additional ELISAs were performed which compared 
capsids containing the HPV 1 L1 protein alone or both 
the L1 and L2 proteins. In all cases, the response to L1- 
only capsids was equal or greater than to the L1L2 cap- 
sids (Table 2). These assays demonstrated that the ma- 
jority of serologic response was directed to the L1 protein 
with minimal to no activity directed against L2 epitopes. 
Sera drawn on Week 7 were also analyzed for reactivity 
in a Western blot assay against either HPV 1 trpE-L1 or 
trpE-L2 fusion proteins (Table 2). Reactivity to the trpE- 
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Fie. 1. Kinetics of the IgG response in mouse sera to HPV 1 capsids by ELISA. The average responses of the individual mice are plotted. Group 
1 (vac/vae), closed square; group 2 (vac/cap), open square; group 3 (cap/vac), closed diamond; group 4 (cap/cap), open diamond; group 5 (vNY/ 
vNY), closed triangle. 
L1 fusion protein was present only in mice that received 
the vaccinia virus recombinant (groups 1-3), with the 
greatest proportion of response in those animals boosted 
with the vaccinia recombinant (groups 1 and 3). Very few 
animals reacted with a trpE-L2 fusion protein (Table 2) 
and again these had received the vaccinia recombinant. 
An ELISA using a carbonate buffer (pH 9.0) for capsid 
attachment and a Western blot assay utilizing sodium 
d0decyl sulfate (SDS)-polyacrylamide gel electrophore- 
sis both test for reactivity against denatured epitopes. 
There was no correlation between those sera that re- 
acted in the ELISA and those that were positive by the 
Western blot, suggesting that the reactive epitopes ana- 
lyzed by these two assays are different. 
Serum IgM and IgA responses 
In a similar fashion, the mouse sera were tested for 
IgM and IgA responses. All the mice in groups 1-4 dem- 
onstrated an IgM serological response that preceded the 
IgG response by 1-2 weeks (Fig. 4). The response was 
sh0rt-lived, lasting only 1-3 weeks. In groups 1-3, no 
IgM response appeared after the boost. Group 4 (cap/ 
cap) that showed the greatest variability in IgG response, 
demonstrated an initial peak of IgM response on Week 
land another at Week 5 (Fig. 4, group 4). Each animal 
had only one IgM response with some animals re- 
sponding at Week 1 and others at Week 5 (data not 
shown). Assays using denatured capsids or capsids con- 
taining only L1 demonstrated that the predominant reac- 
tivity was directed against native L1 epitopes (Table 2). 
The mouse sera were also tested for IgA responses; 
however, no serum IgA response could be demonstrated 
at any time after inoculation. 
IgA response in cervical secretions 
Secretory antibody responses were measured in the 
mice by collecting vaginal secretions at Weeks 1 and 8 
and assaying them for IgA activity against HPV 1 L1L2 
capsids by ELISA. No response was seen in any group 
at Week 1 (data not shown). At Week 8, animals in groups 
1 (vac/vac) and 3 (cap/vac) had the greatest response 
(Fig. 5). This was significantly different from that of group 
4 (cap/cap, P = 0.041, 0.014, respectively) or control 
group 5 (vNY/vNY, P = 0.0096, 0.0028, respectively). In 
addition, group 2 (vac/cap) also had a significant re- 
sponse as compared to control group 5 (P = 0.0012). A 
significant vaginal mucosal antibody response was seen 
only in the animals that were exposed to the vaccinia 
recombinants. There was insufficient amount of vaginal 
secretions to better characterize the reactive antigenic 
site or to measure the total IgA content of the secretions. 
DISCUSSION 
Previous investigators have noted a vigorous antibody 
response to HPV late proteins in the form of empty cap- 
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FiG. 2. Individual mouse response in the five groups. Each symbol 
represents an individual mouse. 
sids (Zhou et al., 1991a; Kimbauer et al., 1992) or virions 
isolated from a nude mouse system (Christensen et aL, 
1990). Rabbits immunized with baculovirus-derived HPV 
11 capsids without adjuvant have produced high titers 
of neutralizing antibodies (N. D. Christensen, personal 
communication). In addition, vaccinia virus recombinants 
that express the HPV 16 L1 protein have been shown to 
produce antibodies to 16 L1 in mice (Zhou et aL, 1990) 
as well as elicit T-cell responses (Zhou et aL, 1991b). 
This study also shows a vigorous IgG serologic response 
to HPV late proteins in mice to either purified capsids or 
vaccinia virus recombinants. The highest titer of re- 
sponse was seen in the animals who received the vac- 
cinia-virus recombinant first and were boosted with puri- 
fied capsid. This is quite similar to the results of Hu et 
aL (1991a) using vaccinia virus recombinants expressing 
gp160 of HIV 1 and boosting with purified gp160. This HIV 
immunization protocol is the basis for a current phase I 
clinical vaccine trial (Cooney et al., 1993). 
The serologic response seen in mice was directed 
mainly against conformational epitopes on L1. This is 
consistent with the recent findings that human sera pre- 
dominantly react to native L1 antigens of HPV 1, 6, 11, 
or 16 (Rose et aL, 1993; Carter et aL, 1994; Kirnbauer et 
aL, 1994) and that neutralizing antibodies in the nude 
mouse system are directed against conformationat epi- 
topes of HPV 11 (Christensen et aL, 1990). Structural 
analysis of in vivo-purified or vaccinia virus-produced 
HPV 1 capsids demonstrated that the majority of the 
outer shell is composed of L1 (Hagensee et al., 1993; 
Baker et al., 1991) and it is not clear if L2 is exposed 
on the surface. However, antibodies recognizing the L2 
protein can be produced when immunizing rabbits with 
HPV 1 L1L2 capsids (Hagensee et al., unpublished ob- 
servations). In addition, Western blot analysis of HPV 
1 L1L2 capsids demonstrates L2 to be present and a 
monoclonal antibody against HPV 1 L2 localizes to cap- 
sids by immune electron microscopy (Hagensee et al., 
1993). It is felt that a portion of the L2 protein is exposed 
on the viral capsid but that this potential antigenic site 
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FIG. 3. Titer of the IgG response in mouse sera at Week 7. Individual mouse sera were diluted and assayed for reactivity to HPV 1 capsids by 
ELISA. The average responses of the individual mice are plotted. Group 1 (vac/vac), closed square; group 2 (vac/cap), open square; group 3 (cap/ 
vac), closed diamond; group 4 (cap/cap), open diamond; group 5 (vNY/vNY), closed triangle. 
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IgG 
ELISA Western blot 
Group L1 -native L1 -denat a L1L2mative L1L2-denat trp-L1 trp-L2 L1 -native 
IgM 
ELISA 
Ll-denat L1L2-native L1L2-denat 
1 (vac/vac) 8/8 b 6/8 8/8 4/5 4/8 2/8 4/4 0/4 8/8 0/6 
2 (vac/cap) 9/9 4/9 9/9 4/7 2/8 1/8 3/3 0/3 9/9 0/4 
3 (cap/vac) 10/10 0/10 10/10 0/5 5/9 0/9 3/3 0/3 10/10 0/4 
4 (cap/cap) 10/10 0/10 10/10 0/6 0/9 0/9 5/5 0/5 10/10 0/6 
5 (vitY/vNY) 0/11 0/5 nt ° nt 0/6 0/6 nt nt 0/11 nt 
a Denatured capsids used in the ELISA. 
b Number of positive responding mice/total number of mice. 
nt, not tested. 
contributes minimally to the antibody response seen in 
mice. 
Denatured epitopes, as detected by Western blot or 
the ELISA using denatured capsids, were seen only in 
micethat received the vaccinia virus recombinant in t.heir 
administration protocol. Production of an antibody re- 
sponse using vaccinia virus recombinants requires the 
animal to take up the virus, express the recombinant 
protein, and present this to the immune system. The re- 
combinant protein can be processed by the cell into pep- 
tide antigens or, in the case of HPV late antigens, be 
presented after assembly of capsids. This allows for 
more potential interactions with the immune system that 
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FIG. 4. Comparison of the IgM (closed squares) and IgG (open 
squares) response in mouse sera to HPV 1 capsids. Plotted are the 
average responses of the groups of mice. 
could lead to antibodies directed against denatured epi- 
topes. The lack of correlation between the Western blot 
assay and the ELISA may be due to the difference in the 
antigen used as well as differences in the preparation 
of antigen. For the ELISA, purified capsids are diluted in 
a high pH carbonate buffer (pH 9.5) and allowed to ad- 
here to the plate overnight. In contrast, the Western blot 
assay used trpE fusion proteins that are placed in SDS, 
reduced by p-mercaptoethanol, boiled, and electropho- 
retically separated in the presence of SDS. There were 
insufficient sera collected to retest the mice either in a 
Western blot assay using capsids as antigen or an ELISA 
using trpE fusion proteins. 
In all animals, the IgG serologic response was pre- 
ceded by an IgM response with no additional IgM re- 
sponse seen with boosting. This is consistent with the 
antibody class switch upon presentation of novel anti- 
gens (Kishimoto and Hirano, 1989). Initial IgM responses 
can be directed at numerous antigenic targets and only 
the most prolific ones persist and switch to IgG (Hasem- 
ann and Capra, 1989). In this study, the IgM response 
seen was only directed against conformational epitopes 
by ELISA. Unfortunately, the amount of sera was limited 
and did not allow for Western blot or extensive ELISA 
analysis of the IgM response. It would be of interest to 
evaluate human populations for possible IgM responses. 
These experiments would predict that a transient IgM 
response will be made upon primary exposure to papillo- 
mavirus antigens. This may provide a serologic test to 
screen for newly acquired HPV infection. However, the 
short-lived nature of the IgM response seen in mice may 
make this assay unfeasible for application to humans. 
Vaccinia virus recombinants have been extensively 
used to express mammalian proteins, produce both hu- 
meral and cellular immune responses, confer protection 
to subsequent pathogenic challenge, and are being used 
in the development of human and animal vaccines (Pic- 
cini and Paoletti, 1988). Parenterally administered poxvi- 
rus-based recombinants have been protective against 
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FIG. 5. IgA antibody response in vaginal secretions to HPV 1 capsids by ELISA. The individual mouse responses are plotted (open squares), The 
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mucosal challenge with feline leukemia virus (Tartaglia 
et al., 1993), avian influenza virus (Taylor et al., 1988), 
and respiratory syncitial virus (RSV) (Murphy etaL, 1989). 
In the study with RSV, significant mucosal antibody was 
elicited by the vaccinia virus recombinants expressing 
either the glycoprotein F or G. The vaccinia virus recom- 
binant was found to be protective in an in vitro neutraliza- 
tion assay and upon challenge to the lower respiratory 
tract of mice. However, these results were not compared 
to animals that were immunized with purified antigens. 
Vaccinia virus recombinants expressing surface anti- 
gens of other STDs (simian immunodeficiency virus, HSV) 
have been protective but only to systemic challenge 
(Paoletti et aL, 1984; Wachman et aL, 1987; Weir et aL, 
1989; Hu et al., 1991 b). It remains to be seen whether the 
use of these recombinants will be effective in preventing 
infection by the genital route. 
In this study, a serum IgA response was not detected. 
Typically, a systemic IgA response is seen concurrently 
with the development of mucosal IgA but this is not al- 
ways the case (McDermott etaL, 1990; Cui eta/., 1991). 
The lack of a serum response may simply reflect the lack 
of sensitivity of the ELISA for IgA. Typically IgA consti- 
tutes only 10-15% of the total serum immunoglobulin. 
This study did show the development of a significant 
vaginal IgA response to HPV 1 capsids in mice that re- 
ceived vaccinia virus recombinants. Total IgA in the vagi- 
nal secretions could not be measured due to an inade- 
quate sample size, therefore, the specific IgA response 
noted was not normalized to the amount of total IgA 
present. This could lead to spurious results particularly 
if there was a great disparity in the amount of secretions 
collected. The amount of secretions collected was felt to 
be constant for all animals with no large variations noted. 
Future experiments in mice and humans are currently in 
progress that will collect a larger sample size that will 
permit total IgA testing as well as better characterization 
of the reacting epitope(s). 
It is unclear how parenteral vaccination with a vaccinie 
recombinant could lead to a mucosal immune response. 
A vaginal IgA response has been seen in guinea pigs 
after subcutaneous injection with HSV antigens (McBride 
et aL, 1988). A simple explanation for these findings is 
that the antibody response seen merely represents blood 
contamination in the vaginal area. This is unlikely due to 
the lack of a serum IgA response in the current study 
and although testing for occult blood was not done, the 
vaginal specimens were not grossly bloody. Another pos- 
sible mechanism is that a serum IgA response was elic- 
ited which was subsequently taken up by the vaginal/ 
cervical cells and then secreted. In humans, serum IgA 
is predominantly monomeric and only a small fraction 
(5% or less) has been found in secretions (Mestecky, 
1987). On the other hand in mice, the majority of the 
serum IgA is multimeric and this may lead to a greater 
proportion being found in secretions (Mestecky, 1987). 
This explanation is again unlikely due to the failure to 
find a serum IgA response. Many investigators have 
noted the production of a mucosal antibody response 
that was distant from mucosal antigenic challenge (Czer- 
kinsky et aL, 1993; Mestecky, 1987). This response pre- 
sumably involves a circulating IgA producing plasma cell 
intermediate. It is possible that vaccination with vaccinia 
recombinants could lead to such a circulating plasma 
cell that then localizes to the vaginal/cervical area as 
well as other mucosal sites. It would be interesting in 
future experiments to concurrently measure salivary or 
stool antibodies. Finally, the tail scarification procedure 
is somewhat close in proximity to the vaginal orifice and 
it is conceivable but unlikely that antigen could have 
been presented directly to the vaginal surface. 
This study did not examine the production of cellular 
immune responses to HPV 1 capsids. Cellular immune 
responses have been shown to be essential in recov- 
ering from viral infections such as influenza (Ada, 1989) 
and herpes viruses (Gelb, 1985; Wildy and Gell, 1985), 
IMMUNOLOGICAL RESPONSE TO HPV 1 181 
bacterial infections such as Listeria monocytogenes, as 
well as parasitic infections (Ada, 1989). Cell-mediated 
immunity is most likely involved in HPV infection. Immu- 
nosuppressed individuals such as renal transplant recip- 
ients and HIV-infected patients have an increased inci- 
dence of HPV-induced lesions such as conylomata and 
0IN (Feingold et aL, 1990; Schneider et aL, 1982). In 
addition, cellular infiltrates are noted in regressing flat 
warts (Thivolet et aL, 1982). Peptide antigens of HPV 
16 L1, E6, and E7 proteins have been found to induce 
proliferation of T-cells and induce cytotoxic T-cells in 
vitro (Strang et al., 1990; Stauss et aL, 1992). Experiments 
evaluating both the cellular and humoral immune re- 
sponses to mucosal HPV types 6 and 16 capsids pro- 
duced in a vaccinia virus system are currently in prog- 
ress. 
rn summary, mice inoculated with purified HPV 1 cap- 
sids or vaccinia virus recombinants expressing HPV 1 
capsid proteins produced a vigorous IgG serum re- 
sponse. This response was preceded by a short-lived 
IgM response that was directed against conformational 
L1 epitopes. Finally, vaginal IgA could only be detected 
in mice presented with the vaccinia recombinant. The 
studies presented here make a framework for future ex- 
periments utilizing genital types of HPV. The role of poxvi- 
ruses in the development of vaccines for sexually trans- 
mitted diseases including HPV should be further ex- 
plored. 
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